Type 2 Diabetes

In older patients receiving medication intensification, no differences were seen in the risk of severe hyperglycemia, severe hypoglycemia, or death at 1 year.

The mean IR of first registered DFU was 2.5 per 1000 person-years for patients with T2D and 1.6 per 1000 person-years for patients with T1D.

Offspring born to mothers with any diabetes diagnosis during pregnancy were more likely to develop any psychiatric disorder or specific disorders, compared to their unexposed peers.

The first iteration of Crisis Point addresses the obesity crisis in the United States and beyond, with expert interviews and discussion.

Dr. Ponder continued his discussion on technology use in pediatric T1D care, focusing on a multidisciplinary care angle and different concepts in treatment.

Dr. Ponder discusses the importance of both clinician and patient learning about new diabetic technologies, focusing on their utility and limitations in the care process.

Episode 4 of Crisis Point asks the question you've been waiting for, "What is blueprint to resolving the obesity crisis?"

Data show 5 of 20 patients with history of MBS in the study experienced the primary composite outcome of IMV and/or death by day 7.

Diabetes progression included greater likelihood of insulin treatment initiation, hyperglycemia, glycemic complications, and glucose-lowering prescriptions.

Episode 3 of Crisis Point examines the regional differences in obesity, from issues with nutrition and food insecurity to the use of the phrase "food desert".

Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

Sotagliflozin reduced HbA1c by 0.42% and heart failure by 32% in comparison to placebo.

Episode 2 of HCPLive Crisis Point tackles the clinical aspects and potential burdens clinicians face in the pursuit of obesity care.

In his recent presentation, Dr. Sperling spoke of how a greater focus needed to be made on the implementation of cardiovascular care strategies, as well as better utilization of health system approaches.

The risk of TB was 48% higher in patients with diabetes compared to those without diabetes, while participants with IFG showed no increased risk of TB incidence.

A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

Women with gestational diabetes face a twice greater risk of developing cardiovascular disease. Investigators are still seeking understanding of the association.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.